77279-24-4

Basic information

• Product Name: TERT-BUTYL 4-(2-HYDROXYETHYL)PIPERAZINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4-(2-HYDROXYETHYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE;BUTTPARK 46\04-31;BOC-N-(2-HYDROXYETHYL)PIPERAZINE;4-(2-HYDROXYETHYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;4-(2-HYDROXYETHYL)-1-PIPERAZINECARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER;1-BOC-4-(2-HYDROXYETHYL)-PIPERAZINE;1-(TERT-BUTOXYCARBONYL)-4-(2-HYDROXYETHYL)PIPERAZINE;1-TERT-BUTYLOXY CARBONYL-4-HYDROXYETHYL PIPERAZINE
• CAS NO: 77279-24-4
• Molecular Formula: C₁₁H₂₂N₂O₃
• Molecular Weight: 230.3
• Product Categories: pharmacetical;Hydroxymethyl's;Pyrans, Piperidines &Piperazines;Piperaizine;Pyrans, Piperidines & Piperazines;Building Blocks;Heterocyclic Building Blocks;Piperazines
• Mol File: 77279-24-4.mol
• Article Data: 63

Chemical Properties

• Melting Point: 39 °C
• Boiling Point: 114°C 0,1mm
• Flash Point: 110 °C
• Appearance: White to pale brown/Solid
• Density: 1.092 g/cm³
• Vapor Pressure: 9.61E-06mmHg at 25°C
• Refractive Index: 1.492
• Storage Temp.: 2-8°C
• PKA: 14.96±0.10(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-(2-HYDROXYETHYL)PIPERAZINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(2-HYDROXYETHYL)PIPERAZINE-1-CARBOXYLATE(77279-24-4)
• EPA Substance Registry System: TERT-BUTYL 4-(2-HYDROXYETHYL)PIPERAZINE-1-CARBOXYLATE(77279-24-4)

Safety Data

• Hazard Codes: C,N,T
• Statements: 36/37/38-50-25
• Safety Statements: 26-36/37/39-61-45
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 77279-24-4(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate, also known as tert-butyl 2-(2-hydroxyethyl)piperazine-1-carboxylate, is a chemical compound with the molecular formula C13H26N2O3. It is a white solid that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. TERT-BUTYL 4-(2-HYDROXYETHYL)PIPERAZINE-1-CARBOXYLATE belongs to the class of piperazine derivatives, which are widely used in the pharmaceutical industry due to their diverse biological activities. Tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate exhibits potential pharmacological properties and may be used as a building block for the development of new drugs. Its structure contains a tertiary butyl group, a piperazine ring, and a carboxylic acid ester functionality, which are essential for its biological and chemical reactivity.

InChI:InChI=1/C11H22N2O3/c1-11(2,3)16-10(15)13-6-4-12(5-7-13)8-9-14/h14H,4-9H2,1-3H3

Upstream product

• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 209667-59-4 tert-butyl 4-(2-ethoxy-2-oxoethyl)piperazine-1-carboxylic acid 
• 103-76-4 1-(2-hydroxyethyl)piperazine 
• 34619-03-9 tert-butyldicarbonate 
• 1426682-55-4 t-butyl 4-pyridyl carbonate 
• 89985-91-1 tert-butyl pyridin-2-yl carbonate 
• 540-51-2 2-bromoethanol 
• 245435-42-1 4-(2-formyloxy-ethyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 191483-37-1 4-[2-(3-Ethoxycarbonyl-benzyloxy)-ethyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 658053-32-8 N-[3-(4-hydroxyphenyl)propionyl]-L-isoleucyl-L-proline 2-[4-(tert-butyloxycarbonyl)piperazin-1-yl]ethyl ester 
• 655225-01-7 tert-butyl 4-(2-bromoethyl)-piperazine-1-carboxylate 
• 845526-55-8 4-[2-(2-ethylsulfanyl-2,2-diphenylacetoxy)ethyl]piperazine-1-carboxylic acid tert-butyl ester 
• 502654-48-0 1-tert-butoxycarbonyl-4-{2-[4-(pyrazol-3-yl)phenyloxy]ethyl}piperazine 
• 945953-41-3 4-(2-oxoethyl)piperazine-1-carboxylic acid tert-butyl ester 
• 845526-56-9 ethylsulfanyldiphenylacetic acid 2-piperazin-1-ylethyl ester 
• 1431773-64-6 N-(6-(2-methylpyrrolidin-1-yl)pyridin-2-yl)-6-(3-(2-(piperazin-1-yl)ethoxy)phenyl)imidazo[1,2-b]pyridazin-8-amine 
• 1420290-86-3 5-chloro-N-(2-chloro-4-nitro-phenyl)-2-(2-piperazin-1-yl-ethoxy)benzamide 
• 1420290-97-6 4-{2-[4-chloro-2-(2-chloro-4-nitro-phenylcarbamoyl)-phenoxy]-ethyl}-piperazine-1-carboxylic acid tert-butyl ester 
• 1007209-78-0 (4-Amino-phenyl)-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-methanone 
• 103-76-4 1-(2-hydroxyethyl)piperazine 
• 1233857-84-5 tert-butyl 4-(2-(4-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)phenoxy)ethyl)piperazine-1-carboxylate 
• 1355554-15-2 N-cyclopentyl-5-(3,5-dimethylisoxazol-4-yl)-2-(2-(piperazin-1-yl)ethoxy)benzenesulfonamide hydrochloride 

Relevant articles and documents

Design, synthesis and antifungal evaluation of borrelidin derivatives

Borrelidin, a nitrile containing 18-membered polyketide macrolide, display potent antifungal activity. In this study, a library of borrelidin derivatives were synthesized. Their structures were elucidated by detailed spectroscopic data analysis. The antifungal activity and cytotoxicity of these target compounds were evaluated by broth microdilution and 3-(4,5-dimethylthiazol-2-yl)-3,5-phenytetrazoliumromide (MTT) methods. Among forty-seven prepared analogues, compound 3b had the inhibitory effect on Candida albicans and Candida parapsilosis (MIC: 50 and 12.5 μg/mL, respectively). Furthermore, compounds 4n and 4r presented better antifungal activity against Aspergillus fumigatus with 12.5 μg/mL MIC value, which were insensitive to borrelidin. Preliminary structure-activity relationships (SAR) revealed that the ester analogues containing fragment -OCH2CH2N- had an important effect on the antifungal activity. Meanwhile, the molecular docking study indicated the carboxyl substituents in BN could provide extra interaction with pathogenic fungal threonyl-tRNA synthetase (ThrRS).

Structure-Activity Relationship Studies Reveal New Astemizole Analogues Active against Plasmodium falciparum in Vitro

In the context of drug repositioning and expanding the existing structure-activity relationship around astemizole (AST), a new series of analogues were designed, synthesized, and evaluated for their antiplasmodium activity. Among 46 analogues tested, compounds 21, 30, and 33 displayed high activities against asexual blood stage parasites (PfNF54 IC50 = 0.025-0.043 μM), whereas amide compound 46 additionally showed activity against late-stage gametocytes (stage IV/V; PfLG IC50 = 0.6 ± 0.1 μM) and 860-fold higher selectivity over hERG (46, SI = 43) compared to AST. Several analogues displaying high solubility (Sol > 100 μM) and low cytoxicity in the Chinese hamster ovary (SI > 148) cell line have also been identified.

FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS

The disclosure provides compounds of formula (I), or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.

TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS

The present invention discloses a series of tricyclic compounds and use thereof in preparing a medicament for treating a disease related to CRBN protein. Specifically, the present invention discloses a derivative compound of formula (1) or a pharmaceutically acceptable salt thereof.